The development of viral vaccines faces persistent scientific and logistical challenges, particularly in the wake of the COVID-19 pandemic. This review critically examines emerging strategies to overcome key barriers in viral vaccine design and deployment. We focus on four major areas: (1) structure-guided antigen engineering to stabilize conformations; (2) the mRNA platform and its delivery system; (3) advanced adjuvant systems that enhance cellular and humoral immunity; and (4) approaches to mitigate immune imprinting and antigenic variability, such as chimeric antigens and glycan shielding. We also explore anti-idiotypic vaccination strategies and the limitations of current animal models in predicting human immune responses. In addition, to address vaccine hesitancy and inequitable access, we advocate for global collaboration in manufacturing, distribution, and public education to ensure inclusive immunization strategies. By integrating molecular insights with platform technologies, we aim to inform the rational design of future vaccines with improved efficacy and public acceptance.
Building similarity graph...
Analyzing shared references across papers
Loading...
Fangfeng Yuan
Martin H. Bluth
Vaccines
Massachusetts Institute of Technology
Wayne State University
Maimonides Medical Center
Building similarity graph...
Analyzing shared references across papers
Loading...
Yuan et al. (Wed,) studied this question.
www.synapsesocial.com/papers/68d461cb31b076d99fa61279 — DOI: https://doi.org/10.3390/vaccines13090979
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: